At a glance
- Originator Tanabe Seiyaku
- Class Anti-ischaemics; Heart failure therapies
- Mechanism of Action Endothelin A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Pulmonary hypertension; Reperfusion injury